Information Provided By: 
Fly News Breaks for July 15, 2015
RCPT, CELG
Jul 15, 2015 | 06:28 EDT
Deutsche Bank analyst Robyn Karnauskas raised her price target for Celgene (CELG) to $175 following the company's acquisition of Receptos (RCPT). Karnauskas believes Receptos' opportunity in multiple sclerosis alone could be enough to justify the price paid with its opportunity in ulcerative colitis potentially being a free call option. She adds the premium paid by Celgene "does not seem to be too hefty." The analyst views the deal as a positive for Celgene and keeps a Buy rating on the name.
News For CELG;RCPT From the Last 2 Days
There are no results for your query CELG;RCPT
